Vertex pharmaceutical’s growth story in biotech with Symdeko’s approval FDA has recently approved Vertex Pharmaceutical’s latest combination treatment, Symdeko, to serve the cystic fibrosis patient population. Symdeko’s annual list price has been set at USD 292,000. Symdeko has paired with a fresh corrector, tezacaftor, with the active ingredient in Kalydeco, ivacaftor. Vertex assumes that the … Continue reading Symdeko’s approval; Erytech target solid tumors; Oncologie snapped bavituximab; Merck delivers